Alyeska Investment Group
IMCR icon

Alyeska Investment Group’s Immunocore IMCR Stock Holding History

Alyeska Investment Group’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-35,000
Closed -$1.49M – 775
2021
Q1 		$1.49M Buy
+35,000
New +$1.56M 0.02% 520

Other funds holding IMCR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BCPEMI
Bain Capital Public Equity Management II Boston, Massachusetts $62.1M AUM 25.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Alyeska Investment Group's IMCR Position: Q2 2021 in Review

Alyeska Investment Group sold out of Immunocore (IMCR) in Q2 2021, closing a stake of 35,000 shares — an estimated $1.49M sold.

Alyeska Investment Group first reported a position in IMCR in Q1 2021 and held it in 1 quarter. The position peaked at $1.49M in Q1 2021. 45 funds tracked by Wall St. Rank hold IMCR as of Q2 2021.

  • Alyeska Investment Group reported no remaining Immunocore position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 35,000 Immunocore shares in Q2 2021, an estimated $1.49M.
  • Alyeska Investment Group first reported a position in Immunocore in Q1 2021 and held it in 1 quarter.
  • Alyeska Investment Group's Immunocore position peaked at $1.49M in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Immunocore as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.